Comparison of the everolimus eluting XIENCE-V* stent with the paclitaxel eluting TAXUS* stent in all-comers: a randomized open label study.
Phase 4
Recruiting
- Conditions
- 10011082outcome PCI treatment
- Registration Number
- NL-OMON35195
- Lead Sponsor
- Medisch Centrum Rijnmond-Zuid
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 1600
Inclusion Criteria
All patients referred for PCI according to dutch and european guidelines
Age between 18-85 years
Exclusion Criteria
1 Expected non-adherence to dual antiplatelet therapy for 1 year (e.g: known allergy to ASA or thienopyridines like clopidogrel)
2 Expected major surgery within 30 days (these patients will receive bare metal stents)
3 Expected loss for follow up
4 Enrollment in another stent study with different stents
5 Inability to implant Taxus or Xience-V stent(s)
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method